Filament Health (FH.NE) shipped their first batch of good manufacturing practices (GMP) certified natural psilocybin into the United States earlier this week, according to a press release. The…
Mushrooms
Braxia Scientific (BRAX.C) announced they will be conducting a randomized clinical trial that will involve giving patients multiple doses of psilocybin. Braxia says this is Canada’s first psilocybin trial…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Novamind (NM.CN) is a company that addresses mental health. Utilizing a network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine. The company states they are…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Mydecine Innovations Group (MYCO.NE) announced they have signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine. The research will be led by Dr. Matthew Johnson…
Revive Therapeutics (RVV.C) announced they are entering into an exclusive license agreement with Puerto Rico Science Technology and Research Trust (PRSTRT) for the intellectual property titled ‘Biologically Active Ganoderma…